Latest News and Press Releases
Want to stay updated on the latest news?
-
TEL-AVIV, Israel, March 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
-
RedHill and Concordia recently entered into an exclusive co-promotion agreement, granting RedHill certain promotion rights in the U.S. for Donnatal®RedHill expects to initiate promotion of Donnatal®...
-
TEL-AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
-
RedHill maintains a strong and debt-free balance sheet with approximately $66 million in cash and cash equivalents at the end of 2016, allowing the Company to continue to execute its development and...
-
Top-line results are expected in the second quarter of 2017 The randomized, double-blind, placebo-controlled Phase III study is evaluating the safety and efficacy of...
-
TEL-AVIV, Israel, Feb. 16, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
-
Top-line results are expected in the second quarter of 2017The randomized, double-blind, placebo-controlled Phase III study is evaluating the safety and efficacy of BEKINDA® 24mg...
-
TEL-AVIV, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
-
TEL-AVIV, Israel, Jan. 12, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
-
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA's Generating...